Brief: Mineralys Therapeutics Presents Subgroup Analyses Of Phase 3 Launch-Htn Trial Demonstrating Efficacy And Safety Of Lorundrostat In Hypertension Participants With High Unmet Medical Need
05/09/2025 15:56
Mineralys Therapeutics Inc MLYS.O: MINERALYS THERAPEUTICS PRESENTS SUBGROUP ANALYSES OF PHASE 3 LAUNCH-HTN TRIAL DEMONSTRATING EFFICACY AND SAFETY OF LORUNDROSTAT IN HYPERTENSION PARTICIPANTS WITH HIGH UNMET MEDICAL NEED Source text: ID:nGNX7sDSz Further company coverage: MLYS.O
Recent news on Mineralys Therapeutics
See all newsBrief: Mineralys Therapeutics Expands Its Board Of Directors With The Appointments Of Kristine Peterson And Lonnel Coats
Mineralys Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway